Affiliation:
1. Kuban State Medical University, Ministry of Health of Russia, Krasnodar
Abstract
Post-COVID syndrome develops after a COVID-19 infection, and is also observed in cases of mild or asymptomatic course of the disease. The most common symptoms of bridge syndrome are asthenia and decreased performance, with further development of cognitive deficit. Taking into account the leading role of immune disorders in the pathogenesis of COVID-19, the use of immunotropic drugs that have both direct activity in relation to immune interactions and those that work indirectly through the reduction of post-stress reactions that can maintain immune dysfunction seems promising. In this regard, Selank is of interest, a peptide created on the basis of the immune regulator tafcin, which has proven itself well in the treatment of a wide range of neurotic and neurosis–like disorders. Objective. To study the efficacy of the drug Selank in patients with complaints of asthenia, decreased performance and emotional disorders that developed after COVID-19 infection. Material and methods. The study included 64 patients divided into 2 groups: Group 1 (n=32) – patients received neuroprotective complex (cholitilin, mexidol, milgamma) and the drug Selank; Group 2 (n=32) – patients received neuroprotective complex (cholitilin, mexidol, milgamma) without the drug Selank. Results. The drug Selank (nasal drops, 1.5 mg) when used at a dose of 2-3 drops 4 times a day for 30 days showed a good effect in patients with asthenia and impaired mental performance. In parallel, relief of anxiety and depressive symptoms was observed. Based on the data obtained, it can be argued that Selank demonstrates a good effect when used in patients with asthenia, which developed as a result of a previous COVID-19 viral infection, with concomitant depressive and anxiety symptoms.
Publisher
Russian Vrach, Publishing House Ltd.
Reference55 articles.
1. Андреева Л.А., Мезенцева М.В., Наровлянский А.Н. и др. Перспективы создания новых пептидных лекарственных препаратов, обладающих противоинфекционной и иммуномодулирующей активностью. Инфекция и иммунитет. 2011; 1 (2): 171–6 [Andreeva L.A., Mezentseva M.V., Narovlianskiy A.N. et al. The perspectives of development of new peptide preparations for clinical use which have anti-infection and immune-modulating activity. Infekc immun. 2011; 1 (2): 171–6 (in Russ.)].
2. Белоглазов В.А., Вербенко В.А., Лугачев Б.И. Применение интраназального препарата Селанк 0,15% с целью психофармакологической коррекции в комплексной терапии пациентов с бронхиальной астмой. Поликлиника. 2019; 3: 34–8 [Beloglazov V.A., Verbenko V.A., Lugachov B.I. The use of intranasal drug Selank 0,15% for the purpose of psychopharmacological correction in the treatment of patients with bronchial asthma. Poliklinika. 2019; 3: 34–8 (in Russ.)].
3. Вербенко В.А., Шакина Т.А. Новые возможности потенцирования действия селективных ингибиторов обратного захвата серотонина регуляторным пептидом Селанк при терапии тревожно-депрессивных расстройств. Врач. 2019; 30 (10): 76–81 [Verbenko V., Shakina T. New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders. Vrach. 2019; 30 (10): 76–81 (in Russ.)]. DOI: 10.29296/25877305-2019-10-16
4. Особенности анксиолитического и стрессопротективного действия пептидного препарата Селанк® при терапии расстройств адаптации и посттравматического стрессового расстройства. Медицинский алфавит. 2017; 3 (32): 21–6 [Verbenko V.A., Shakina T.A. Effectiveness of new synthesized analogue of endogenous peptide taftcin – Selank in therapy of adjustment and posttraumatic stress disorders. Medical alphabet. 2017; 3 (32): 21–6 (in Russ.)].
5. Вербенко В.А., Федоров В.Н. Оптимизация терапии тревожных расстройств. Таврический журнал психиатрии. 2016; 20 (3): 5–14 [Verbenko V.A., Fedorov V.N. Optimization of therapy for anxiety disorders. Tauride Journal of Psychiatry. 2016; 20 (3): 5–14 (in Russ.)].